Estradiol in premenstrual asthma: a double-blind, randomized, placebo-controlled, crossover study

Area of Science:

• Reproductive Endocrinology
• Pulmonology
• Clinical Pharmacology

Background:

• Asthma symptoms can fluctuate during the menstrual cycle, particularly in premenstrual asthma.
• The role of estradiol in premenstrual asthma exacerbations is not fully understood.
• Exogenous estradiol administration is a potential therapeutic avenue.

Purpose of the Study:

• To investigate the effects of exogenous estradiol on asthma symptoms and pulmonary function in women with premenstrual asthma.
• To assess the impact of estradiol on quality of life and airway inflammation biomarkers.
• To characterize asthma symptom patterns across the menstrual cycle.

Main Methods:

• A double-blind, randomized, placebo-controlled, crossover study was conducted.
• Twelve women with premenstrual asthma received oral estradiol or placebo during the premenstrual phase over two cycles.
• Daily peak expiratory flow (PEF) and asthma symptoms were recorded; spirometry and biomarker analysis were performed.

Main Results:

• No significant differences were observed in daily PEF or asthma symptom scores between estradiol and placebo cycles.
• Estradiol administration did not significantly alter spirometry results, quality of life, or biomarkers of airway inflammation.
• A numerical, but not statistically significant, reduction in asthma symptom severity was noted with estradiol.

Conclusions:

• Exogenous estradiol did not demonstrate a significant therapeutic effect in women with mild, well-controlled premenstrual asthma.
• The placebo effect appears to be prominent in premenstrual asthma.
• Further research is needed in populations with more severe asthma to elucidate underlying mechanisms.